Dr Pedro Barata speaks to ecancer about a phase 3 lead-in analysis from the ProstACT global study evaluates 177Lu-rosopatamab, a PSMA-targeted radioligand therapy, in combination with standard of care in patients with metastatic castration-resistant prostate cancer (mCRPC).

He says that early findings demonstrate a manageable and predictable safety profile, with mainly transient haematologic adverse events and no new safety signals identified.

Importantly, no treatment-related deaths were reported, and non-haematologic side effects were generally mild.

Pharmacokinetic and dosimetry analyses showed bi-exponential clearance and sustained tumour uptake, with higher radiation exposure in tumour lesions compared to normal tissues.

Overall, these results support the continued development of 177Lu-rosopatamab as a promising targeted therapy in mCRPC, with encouraging safety and tumour-targeting characteristics.

Other authors that took part in this analysis: Gary Tincknell, David M. Gill, Simon Y. Fu, Aviral Singh, Alton O. Sartor, David Cade, Neeraj Agarwal.